BioVector? A2143G 突變型幽門螺桿菌菌株 / BioVector? A2143G Mutant Helicobacter pylori Strain

通用定義 / General Definition:

BioVector? A2143G 是幽門螺桿菌 (Helicobacter pylori) 的一種關鍵耐藥表型株。該菌株的 23S rRNA 基因 V 區(qū)第 2143 位點發(fā)生了從腺嘌呤 (A) 到鳥嘌呤 (G) 的點突變。這一特定突變是全球范圍內(nèi)幽門螺桿菌對克拉霉素 (Clarithromycin) 產(chǎn)生獲得性耐藥的最常見機制（占比通常超過 70%）。A2143G 突變導致克拉霉素無法有效結合細菌核糖體 50S 亞基，從而抑制其蛋白質(zhì)合成阻斷作用。它是研究抗生素耐藥機制、臨床分子診斷試劑開發(fā)及新型根除方案評估的“金標準”耐藥模型。

BioVector? A2143G is a critical drug-resistant phenotypic strain of Helicobacter pylori. It harbors a point mutation at position 2143 of the 23S rRNA gene (Domain V), characterized by an adenine (A) to guanine (G) transition. This specific mutation is the most prevalent mechanism globally (often exceeding 70%) for acquired resistance to clarithromycin in H. pylori. The A2143G mutation prevents clarithromycin from binding effectively to the 50S ribosomal subunit, thereby neutralizing its ability to inhibit bacterial protein synthesis. It serves as a "gold standard" resistance model for studying antibiotic resistance mechanisms, developing clinical molecular diagnostic kits, and evaluating novel eradication therapies.

BioVector? A2143G 技術說明書 (Technical Datasheet)

中文版說明書 (Chinese Datasheet)

1. 產(chǎn)品基本信息

• 產(chǎn)品名稱： BioVector? A2143G 突變型幽門螺桿菌

• 基因型特征： 23S rRNA A2143G 點突變（可通過 PCR-RFLP 或測序驗證）。

  
  

• 耐藥表型： 對克拉霉素具有高水平耐藥性（MIC 值通常 $\ge$ 1.0 $\mu$g/mL）。

• 形態(tài)特征： 革蘭氏陰性，微需氧，呈弧形或螺旋狀桿菌。

2. 培養(yǎng)條件

• 培養(yǎng)基： BioVector? 哥倫比亞血瓊脂 (CBA) 或 威爾金斯-查爾格倫瓊脂，需添加 7% - 10% 脫纖維羊血。

• 培養(yǎng)環(huán)境：微需氧條件 ($5\% \ O_2, 10\% \ CO_2, 85\% \ N_2$)。

• 培養(yǎng)溫度： 37 攝氏度。

• 濕度要求： 高濕度環(huán)境（建議放置水盤）。

• 培養(yǎng)周期： 3 - 5 天可見細小、透明或半透明菌落。

3. 菌株應用

• 耐藥診斷檢測： 用于驗證實時熒光 PCR (qPCR) 或基因芯片探測 A2143G 突變的準確性。

• 藥物開發(fā)： 篩選能夠克服 A2143G 突變的新型大環(huán)內(nèi)酯類藥物或聯(lián)合用藥方案。

• 根除策略評估： 在體外模擬胃酸環(huán)境下，評估不同抗生素組合對該耐藥株的殺傷效率。

4. 注意事項

• 遺傳穩(wěn)定性： 在無壓力培養(yǎng)下，耐藥性較為穩(wěn)定，但仍建議在培養(yǎng)基中定期加入低濃度克拉霉素以維持壓選擇。

• 安全性： 屬于生物安全二級 (BSL-2) 致病菌，具有致癌潛能，操作需極其謹慎。

English Datasheet

1. General Product Information

• Product Name: BioVector? A2143G Mutant Helicobacter pylori Strain

• Genotypic Profile: A2143G point mutation in the 23S rRNA gene (validatable via PCR-RFLP or NGS).

• Resistance Phenotype: High-level resistance to Clarithromycin (typically MIC $\ge$ 1.0 $\mu$g/mL).

• Morphology: Gram-negative, microaerophilic, curved or spiral-shaped rod.

  
  

2. Culture Conditions

• Media: BioVector? Columbia Blood Agar (CBA) or Wilkins-Chalgren Agar, supplemented with 7% - 10% defibrinated sheep blood.

• Environment:Microaerophilic conditions ($5\% \ O_2, 10\% \ CO_2, 85\% \ N_2$).

• Temperature: 37 degrees Celsius.

• Humidity: High humidity is essential (use of a water tray is recommended).

• Growth Period: Small, translucent colonies appear within 3 to 5 days.

3. Applications

• Molecular Diagnostics: Serving as a positive control for qPCR or LAMP assays designed to detect the A2143G clarithromycin-resistance marker.

• Antimicrobial Discovery: Screening for next-generation macrolides or potentiators capable of overcoming the A2143G binding interference.

• Eradication Modeling: Evaluating the bactericidal efficacy of various antibiotic combinations against resistant strains in vitro.

4. Key Usage Notes

• Phenotypic Maintenance: While the mutation is genetically stable, BioVector? recommends occasional subculturing on media containing clarithromycin to maintain selection pressure.

• Pathogen Safety: Classified as Biosafety Level 2 (BSL-2). H. pylori is a Group 1 carcinogen; rigorous aseptic technique and proper containment are mandatory.

注意 / Note: 與 A2142G 突變相比，A2143G 突變通常與更低的根除成功率相關。BioVector? 建議在進行對比實驗時，同時使用 A2142G 菌株和敏感型野生型 (Wild-type) 菌株作為對照。

Compared to the A2142G mutation, the A2143G mutation is often associated with lower clinical eradication rates. BioVector? recommends using the A2142G strain and a wild-type susceptible strain as parallel controls in comparative studies.

BioVector NTCC質(zhì)粒載體菌株細胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址

http://www.nedfriskphoto.com